Welcome to our dedicated page for V.F. SEC filings (Ticker: VFC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking five powerhouse brands across three business coalitions means VF Corporation’s disclosures are anything but light reading. Revenue swings between Vans and The North Face, timber sourcing commitments at Timberland, and Wrangler’s inventory cycles all live inside hundreds of EDGAR pages. If you’ve ever asked, “Where can I find VF Corporation’s quarterly earnings report 10-Q filing?” or needed VF Corporation insider trading Form 4 transactions before a product launch, you know the research pain.
Stock Titan solves it. Our platform delivers AI-powered summaries that turn dense 10-K footnotes into plain-English insights. Want a quick view of currency impacts on European sales? It’s highlighted. Need VF Corporation Form 4 insider transactions real-time? Alerts hit your dashboard seconds after the filing posts. We cover every staple form—10-K, 10-Q, 8-K, Form 4, and the proxy statement—so you can move from scrolling to decision-making faster.
Each filing type unlocks different questions investors ask every quarter:
- Annual report 10-K simplified: Brand-level revenue, segment margins, supply-chain risk.
- Quarterly earnings report 10-Q filing: Seasonal wholesale trends and inventory positions.
- 8-K material events explained: Leadership changes or brand acquisitions that shift strategy.
- Proxy statement executive compensation: How incentives align with Vans or Timberland growth.
- Executive stock transactions Form 4: Monitor insider buying patterns before new product drops.
Because filings update quickly, our system streams documents in real time, ensuring you never miss a VF Corporation earnings report filing analysis. Stop searching, start understanding—understanding VF Corporation SEC documents with AI is now a click away.
FB Financial Corp. (FBK) – Insider Form 4 filing dated July 1, 2025
Director J. Henry Smith IV reported the acquisition of 42,180 common shares held directly and 584 shares held indirectly for the benefit of his children. The shares were not purchased on the open market; they were issued in exchange for Smith’s holdings of Southern States Bancshares, Inc. (SSBK) as part of the SSBK-FBK merger that became effective on July 1, 2025. Under the merger agreement, each SSBK share converted into 0.8 share of FBK common stock, with cash paid for fractional shares. The filing confirms Smith’s post-merger beneficial ownership of 42,180 direct and 584 indirect shares. No derivative securities or sales were reported.
Forager Capital Management, LLC, together with its affiliated investment vehicle Forager Fund, L.P. and principals Edward Kissel and Robert MacArthur, has filed a Schedule 13G disclosing ownership of 2,186,472 shares of Viemed Healthcare, Inc. (VMD) common stock.
The position represents 5.5 % of Viemed’s 39.52 million shares outstanding as reported in the company’s 10-Q for the quarter ended 31 Mar 2025. Because the stake exceeds the 5 % threshold, the group is required to disclose its holdings under Section 13(d) of the Exchange Act. The filing is made pursuant to Rule 13d-1(b), indicating that the investors view the holding as passive rather than activist.
Voting and dispositive powers are split as follows: (i) Forager Fund and Forager Capital Management each hold sole voting and dispositive power over the full 2.19 million shares; (ii) Messrs. Kissel and MacArthur share voting and dispositive power over the same shares through their control of the fund and general partner. No other party is reported to have an economic interest in the shares.
The event date is 24 Jun 2025, with the joint filing signed on 1 Jul 2025. The certification clause confirms that the securities were not acquired with the intent to change or influence control of the issuer.
- The disclosure introduces a new institutional shareholder representing a sizeable block for a small-cap healthcare company.
- Filing type (Schedule 13G vs. 13D) suggests a passive, long-only orientation, reducing immediate governance or strategic pressure on Viemed.
BP Prudhoe Bay Royalty Trust (BPT) filed an 8-K detailing two material developments that negatively affect unitholders. First, the Trust confirmed it received no royalty payment for the quarter ended June 30 2025; consequently, no quarterly cash distribution will be made. Because the Trust formally terminated at 11:59 p.m. on December 31 2024, the trustee -- The Bank of New York Mellon Trust Company, N.A. -- is now focused solely on winding-up activities rather than ongoing operations.
Second, the Trust disclosed that it failed to regain compliance with NYSE Rule 802.01C after its unit price averaged below $1.00 for 30 consecutive trading days. As a result, the NYSE suspended trading and initiated delisting proceedings effective June 30 2025. Beginning July 1 2025, the units trade on the OTC Pink market under the temporary symbol “BPPTU.” OTC Pink offers significantly less visibility, lower regulatory oversight and potentially reduced liquidity, all of which may further depress unit prices and complicate trade execution.
The combined cessation of royalty income, trust termination and migration to an over-the-counter venue materially diminish the investment thesis for remaining unitholders. Management does not assure that an active or efficient secondary market will develop on OTC Pink, nor that broker-dealers will continue quoting the security. Investors should also note that the furnished information is not deemed "filed" for Exchange Act liability purposes.